Accounting for approximately 12% of the entire fungal infection treatments space, onychomycosis treatment has been witnessing a high prevalence-low awareness scenario over the years. However, ...

TOPICA Pharmaceuticals, Inc., has announced positive results from its Phase 1/2a trial evaluating the safety, tolerability and pharmacokinetics of a 10% solution of luliconazole after maximal use ...

New York, March 23, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Onychomycosis Market Size, Share & Industry Trends Analysis Report By Type, By Treatment, By ...

Valeant announced that the FDA has approved Jublia (efinaconazole 10%) topical solution for the treatment of onychomycosis of the toenails (distal lateral subungual onychomycosis [DLSO]). Jublia is ...

Hallux Inc., a clinical stage pharmaceutical company, today announced that patient screening has begun for a phase 2 clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics ...

LONDON--(BUSINESS WIRE)--Technavio has announced their latest drug pipeline analysis report on onychomycosis. The report includes a detailed analysis of the pipeline molecules under investigation ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A 4-year-old boy presents with concern ...

The US Food and Drug Administration (FDA) has approved efinaconazole 10% topical solution (Jublia, Valeant Pharmaceuticals) for the treatment of onychomycosis of the toenail, the company announced ...